Andere talen Biogen Inc.

Aandelen

BIIB

US09062X1037

Farmaceutische producten

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 06-12-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
157,78 ^USD	-0,93%		-1,77%	-39,03%

06/12	Glaxosmithkline werkt samen met Muna Therapeutics aan de ziekte van Alzheimer	FW
05/12	BIOGEN INC. : Morgan Stanley is Neutraal over het aandeel	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Biogen Says Leqembi Got Approval to Treat Early Alzheimer's Disease in Mexico	05/12
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico	05/12
"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico	05/12
Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" for the Treatment of Early Alzheimer's Disease in Mexico	05/12
Biogen, Eisai Launch Alzheimer's Drug Leqembi in South Korea	29/11
Eisai Co., Ltd. - LEQEMBI for the Treatment of Alzheimer's disease Launched in South Korea	28/11
Biogen : lance son Leqembi en Corée du Sud	28/11
"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea	28/11
Eisai Co., Ltd. and Biogen Inc. Announce "LEQEMBI®" for the Treatment of Alzheimer's Disease Launched in South Korea	28/11
Biogen : “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South Korea	28/11
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan	26/11
BIOGEN : Jefferies confirme sa cible dans l'attente d'Ocrevus	25/11
European Commission Approves Samsung Bioepis, Biogen's Biosimilar Opuviz	21/11
UCB - Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity	20/11
Biogen : to Participate in the 7th Annual Evercore HealthCONx Conference	19/11
Samsung Bioepis and Biogen Receive European Commission Approval for Aflibercept Biosimilar, OPUVIZ	19/11
Biogen, Partner Say Late-Stage Trial of Lupus Erythematosus Drug Candidate Met Primary Endpoint	19/11
UCB : résultats de phase 3 positifs dans le lupus	19/11
Biogen : résultats de phase 3 positifs dans le lupus	19/11
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity	19/11
Quiet before the earnings quake	18/11
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ	18/11
Analyst recommendations: Biogen, HP, Moderna, Shell...	18/11
WDH/Erste Alzheimer-Therapie in EU zur Zulassung empfohlen	14/11
Alzheimer: le régulateur européen approuve pour certains patients un traitement	14/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Biogen Inc.

Aandelen

BIIB

US09062X1037

Farmaceutische producten

Andere talen

Filters